Behavioral Activation and Acceptance and Commitment Therapy in the Treatment of Anxiety and Depression in Cancer Survivors: A Randomized Clinical Trial

Fernández-Rodríguez, Concepción; González-Fernández, Sonia; Coto-Lesmes, Rocío; Pedrosa, Ignacio

doi:10.1177/0145445520916441

Cited by 27 publications

(27 citation statements)

References 52 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…There is some evidence that change in more central symptoms predict changes in other symptoms (e.g., Rodebaugh et al, 2018), which suggests that interventions focusing on the manipulation of psychomotor activity, like mindfulness‐based approaches, relaxation exercises, or behavioral activation, should be highly effective especially in comorbid patients. Recent findings suggest stronger effects for behavioral activation when compared to acceptance and commitment therapy (Fernández‐Rodríguez et al, 2020). However, it is still unclear whether interventions could target single symptoms (Bringmann & Eronen, 2018) and there is some evidence that current therapeutic interventions target multiple symptoms (Blanken et al, 2019; Boschloo et al, 2019).…”

Section: Discussionmentioning

confidence: 99%

Unraveling the comorbidity of depression and anxiety in a large inpatient sample: Network analysis to examine bridge symptoms

Kaiser

Herzog

Voderholzer

et al. 2021

Depression and Anxiety

121

View full text Add to dashboard Cite

Background Comorbidities in mental disorders are often understood by assuming a common cause. The network theory of mental disorders offers an alternative to this assumption by understanding comorbidities as mutually reinforced problems. In this study, we used network analysis to examine bridge symptoms between anxiety and depression in a large sample. Method Using data from a sample of patients diagnosed with both depression and an anxiety disorder before and after inpatient treatment (N = 5,614, mean age: 42.24, 63.59% female, average treatment duration: 48.12 days), network models of depression and anxiety symptoms are estimated. Topology, the centrality of nodes, stability, and changes in network structure are analyzed. Symptoms that drive comorbidity are determined by bridge node analysis. As an alternative to network communities based on categorical diagnosis, we performed a community analysis and propose empirically derived symptom subsets. Results The obtained network models are highly stable. Sad mood and the inability to control worry are the most central. Psychomotor agitation or retardation is the strongest bridge node between anxiety and depression, followed by concentration problems and restlessness. Changes in appetite and suicidality were unique to depression. Community analysis revealed four symptom groups. Conclusion The estimated network structure of depression and anxiety symptoms proves to be highly accurate. Results indicate that some symptoms are considerably more influential than others and that only a small number of predominantly physical symptoms are strong candidates for explaining comorbidity. Future studies should include physiological measures in network models to provide a more accurate understanding.

show abstract

Section: Discussionmentioning

confidence: 99%

Unraveling the comorbidity of depression and anxiety in a large inpatient sample: Network analysis to examine bridge symptoms

Kaiser

Herzog

Voderholzer

et al. 2021

Depression and Anxiety

121

View full text Add to dashboard Cite

show abstract

“…Psychological flexibility and adjustment to the diagnosis and treatment are predictors of better outcomes, and might be the mechanism by which therapeutic efforts might be helpful 92 . Indeed, acceptance and commitment therapy encourages psychological flexibility and is being tested in many chronic conditions including cancer survivors, and may have a place in the care of dialysis patients living with uncertainty 93 .…”

Section: Discussionmentioning

confidence: 99%

A Systematic Review of the Evidence on Inflammation in Depressive Illness and Symptoms, in Chronic and End Stage Kidney Disease

Jayakumar¹,

Jennings²,

Halvorsrud³

et al. 2021

Preprint

View full text Add to dashboard Cite

BackgroundDepressive illness and symptoms are known to be common in physical health problems and are present in at least a third of people with chronic kidney disease and end stage renalfailure (CKD/ESKD). Depressive illness and symptoms in CKD/ESKD complicates care, is associated with a shorter life expectancy, and may arise in response to inflammation.MethodsWe undertook a systematic review of studies including measures of depression and inflammatory markers in CKD/ESKD. The protocol was pre-registered with PROSPERO: CRD42019141305. Data base searches were completed in 2019 and repeated in May 2020. We assessed study quality, and undertook a narrative synthesis as well as meta-analyses of cross-sectional and longitudinal studies, examining associations between depressive states and inflammatory markers.ResultsThere was significant heterogeneity in study quality, comorbidities, samples, depression measures, and study design, as well as in the specific measured inflammatory markers.Overall, there is some evidence for associations of IL6 and CRP with depressive illness and symptoms, with inconclusive or contradictory evidence for other inflammatory markers. There were few intervention studies. Studies of samples with physical comorbidity and higher rated quality were more likely to show positive associations. There were few longitudinal studies.ConclusionsThere is some evidence of inflammation being an important correlate of depressive illness and symptoms in the presence of physical health comorbidities. Better research designs areneeded including a range of inflammatory markers.

show abstract

“…A depressão coloca-se como uma das principais morbidades psiquiátricas do doente oncológico (ERIM et al, 2019;HORTENSE;BERGEROT;DOMENICO, 2020;NAZARÉ et al, 2020;SILVA;SILVA;BARROS, 2021) ou entre aqueles sobreviventes de câncer (JEAN;SYRJALA, 2017;CHAVES et al, 2021;FERNÁNDEZ-RODRÍGUEZ et al, 2021). Representa um transtorno afetivo que se caracteriza por uma alteração psíquica e orgânica global, promovendo mudanças na forma como o indivíduo atribui valor à realidade e à vida (NGUYEN;KIMBERLY;YATES, 2018).…”

Section: Introductionunclassified

“…Desde o diagnóstico do câncer, o indivíduo fica susceptível à depressão, podendo persistir o risco durante a terapêutica (NGUYEN; KIMBERLY; YATES, 2018) e após sobreviver à doença (JEAN;SYRJALA, 2017;CHAVES et al, 2021;FERNÁNDEZ-RODRÍGUEZ et al, 2021). Importante mencionar que -o uso de terapias antineoplasicas como Interferon, vimblastina, vincristina, asparaginase, entre outros quimioterápicos e corticoides, levam a quadro depressivo havendo a possibilidade a não adesão ao tratamento‖ (NAZARÉ et al, 2020, p. 84).…”

Section: Introductionunclassified

Sintomas depressivos entre sobreviventes de câncer: frequência e fatores de risco

Sousa¹,

Azevedo

Figueiredo

et al. 2021

CONJ

View full text Add to dashboard Cite

Objetivou-se identificar a frequência e fatores de risco para sintomas depressivos entre sobreviventes de câncer. Foi realizada uma revisão integrativa, em que se utilizaram os Descritores em Ciências da Saúde associados: depressão e sobreviventes de câncer, em suas versões portuguesas e inglesas. A pesquisa ocorreu no portal da Biblioteca Virtual em Saúde e na U.S. National Library of Medicine. Pré-selecionaram-se 361 documentos e após aplicação dos critérios de elegibilidade, foram incluídos 11 estudos. Os estudos indicaram que a depressão é comum entre os indivíduos sobreviventes de câncer, mas que a frequência e a gravidade dos sintomas depressivos variam, conforme fatores de exposição. Entre os fatores de risco, os mais citados foram os sociais, econômicos, fatores de estilo de vida e os clínicos. Os achados alertam para a observância de fatores de risco entre indivíduos com neoplasias e, especialmente, entre os sobreviventes de câncer. Assim sendo, é fundamental adotar estratégicas preventivas e de promoção da saúde.

show abstract

Behavioral Activation and Acceptance and Commitment Therapy in the Treatment of Anxiety and Depression in Cancer Survivors: A Randomized Clinical Trial

Cited by 27 publications

References 52 publications

Unraveling the comorbidity of depression and anxiety in a large inpatient sample: Network analysis to examine bridge symptoms

Unraveling the comorbidity of depression and anxiety in a large inpatient sample: Network analysis to examine bridge symptoms

A Systematic Review of the Evidence on Inflammation in Depressive Illness and Symptoms, in Chronic and End Stage Kidney Disease

Sintomas depressivos entre sobreviventes de câncer: frequência e fatores de risco

Contact Info

Product

Resources

About